Asthma

Francesca Puggioni, MD, discusses real-world exacerbations, biomarker-driven access, and barriers to earlier biologic use in asthma and COPD.

Wildfire smoke from US and Canadian fires is worsening air quality, increasing asthma risks and prompting public health guidance.

Voice changes may help detect asthma and COPD exacerbations early, supporting future remote disease monitoring.

Joseph K. Han, MD, discusses upstream biologics, verekitug, and the future of chronic rhinosinusitis with nasal polyps treatment.

Phase 3 SUNRISE data show tezepelumab reduced oral corticosteroid use while maintaining asthma control in severe asthma.

Asthma and Allergy Awareness Month shines light on the ways that asthma can affect long-term health.

The approval is expected to offer more affordable treatment options and potentially reduce asthma-related complications nationwide.

Twice-yearly depemokimab cuts asthma exacerbations in phase 3 trials for patients aged 12 and older with severe eosinophilic asthma.

Patients hospitalized for bronchiectasis exacerbations face higher mortality, longer stays, and greater costs than those with COPD or asthma.

A digital asthma self-management program enhanced symptom control; however, it revealed racial disparities in engagement, highlighting the need for culturally tailored interventions.

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

The legacy of redlining continues to harm minority health, with Black individuals facing higher rates of health issues, linked to environmental factors and limited access to resources in regions previously redlined.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies.

Researchers link vaccination and reduced asthma symptoms; providers warn against overburdening and security risks; insurers’ practices lead to questionable diagnoses

Underserved communities, already facing higher asthma prevalence due to social determinants of health, are disproportionately affected by the impact climate change is having on asthma exacerbations. Potential solutions include education for patients and health care providers, climate litigation to establish environmental rights, and policy changes to curb climate change.

Asthma is worsening under the effects of climate change, such as air pollution and pollen production, especially for underserved populations.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib.

Idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and other interstitial lung diseases are more significantly associated with poor 30-day outcomes from COVID-19 compared with asthma.

Black children with asthma are disproportionately exposed to asthma triggers and access barriers, according to one study.